Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meropenem PK in Early Severe Sepsis
NCT02213796Phase 4Completed
- Start
- Jan 2013
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of meropenem in sepsis and septic shock. Primary endpoint: Concentration of meropenem in plasma at 16 hours. Started Jan 2013; status: completed.
02
Drugs
meropenem
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NCT02213796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02213796.